SCHEMBL742570

SCHEMBL742570

CCOC(=O)n1nc(NC(=O)c2cccn2C)c2cc(C(=O)O)sc21

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
HPGD P15428 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
CASP3 P42574 2/20 0.40
SENP8 Q96LD8 2/20 0.40
SENP7 Q9BQF6 2/20 0.40
SENP6 Q9GZR1 2/20 0.40
POLB P06746 2/20 0.40
NPC1 O15118 1/20 0.40
PKM P14618 1/20 0.40
RAB9A P51151 1/20 0.40
KDM4E B2RXH2 7/20 0.39
MAPT P10636 2/20 0.37
TP53 P04637 2/20 0.37
HDAC6 Q9UBN7 2/20 0.37
HSD17B10 Q99714 2/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
UBE2N P61088 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL741773 0.89 KDM4E (0.39) ALDH1A1HPGDSMN1; SMN2CASP3SENP8
SCHEMBL740983 0.87 AURKA (0.39) ALDH1A1HPGDSMN1; SMN2CASP3SENP8
SCHEMBL739674 0.86 ALDH1A1 (0.36) ALDH1A1HPGDSMN1; SMN2CASP3SENP8
SCHEMBL741012 0.82 KDM4E (0.47) ALDH1A1HPGDSMN1; SMN2POLBNPC1
SCHEMBL739402 0.81 KDM4E (0.46) ALDH1A1HPGDSMN1; SMN2NPC1PKM
SCHEMBL742843 0.80 LMNA (0.47) ALDH1A1HPGDKDM4EMAPTTP53
SCHEMBL1779798 0.79 KDR (0.40) ALDH1A1HPGDSMN1; SMN2NPC1RAB9A
SCHEMBL741290 0.79 P2RY14 (0.40) ALDH1A1HPGDSMN1; SMN2NPC1KDM4E
SCHEMBL1780658 0.78 ALDH1A1 (0.48) ALDH1A1HPGDSMN1; SMN2RAB9AKDM4E
Hydrochloric Acid SCHEMBL741106 0.77 AURKA (0.47) NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481584-B2 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-07-09 US disclosed
US-20120165311-A1 1H-THIENO[2,3-C]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-06-28 US disclosed
US-8138217-B2 Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-03-20 US disclosed
EP-1711177-B1 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS PFIZER ITALIA SRL (IT) 2008-05-28 EP disclosed
EP-1711177-A1 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS Pfizer Italia S.r.l. (IT) 2006-10-18 EP disclosed
US-20050187209-A1 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors PHARMACIA ITALIA S.P.A. (IT) 2005-08-25 US disclosed
WO-2005074922-A1 1H-THIENO[2,3-c]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS PFIZER ITALIA S.R.L. (IT) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165311-A1 1H-THIENO[2,3-C]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K3 ALDH1A1 1584/4885HPGD 1590/4885SMN1; SMN2 3732/4885
US-20050187209-A1 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors MAP3K19, MAP3K1, MAP3K3 ALDH1A1 1516/4885HPGD 1650/4885SMN1; SMN2 3688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.